Ok overdrivelse fremmer forståelsen. AZ Validere som sådan ikke selve NS2359. Men de validerer den mekanisme der ligger bag NS2359. Nemlig det at man vælger at ramme både serotonin, dopamin og noradrenalin. Altså en TRI (triple (3) reuptake inhibition) De nuværende mest solgte stoffer rammer enten kun serotonin (danske Lundbecks Cipralex) eller serotonin/noradrenalin. (Effexor og Cymbalta)
Det betyder nu endnu et big pharma selsskab anser TRI som den næste generations anti lykkepiller.
NS2359 er det TRI stof der er længst fremme i udviklingen. Resultater fra de 2 fase 2b forsøg bør foreligge seneste medio marts. (resultatet fra det ene forsøg har været kendt af GSK og muligvis også NS i mere end 1 mdr)
AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
Posted February 9, 2009
AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
Agreement includes research collaboration to generate follow-up TRI compounds
WILMINGTON, Del., Feb. 9 /PRNewswire-FirstCall/ -- AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds. The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds. Financial details were not disclosed.
Current classes of antidepressant therapies such as selective serotonin (SSRI) and dual serotonin/norepinephrine (SNRI) reuptake inhibitors are proven treatments for depression and anxiety. However, they only address the imbalances of one or two of the neurotransmitters in the brain.
Paul R. Carlier, Professor of Organic and Medicinal Chemistry at Virginia Tech, explains, "Together with our colleagues at Mayo Clinic, we have been seeking wider-spectrum behavior and have developed a portfolio of TRIs to address imbalances associated with the three major neurotransmitters. Besides incorporating all the benefits associated with serotonin and norepinephrine inhibition, our TRI compounds include the additional action of the dopamine neurotransmitter. We are excited to discover additional compounds that work through this unique mechanism."
Elliott Richelson, M.D., Mayo Clinic, co-inventor of the technology adds, "Through our clinical practice, we recognize the need for improved therapies to treat individuals suffering from depression or anxiety. The additional dopamine action of our TRI compounds has the potential to deliver a superior antidepressant in terms of greater efficacy and an improved side effect profile. By collaborating with AstraZeneca, a company with a strong history of developing new medicines, we have the opportunity to both advance and expand upon these scientific discoveries to address better the needs of patients worldwide."
Christer Kohler, Vice President for AstraZeneca's Global Discovery Research Area focused on Central Nervous System & Pain, says "Besides enabling us to harness the combined power of two outstanding, world-class institutions, this agreement also establishes a strong footing for AstraZeneca in the strategically important TRI research area. We continue to build alliances and collaborations within the scientific community and this deal is another example of our strong commitment and ability to leverage innovation with the aim of making a meaningful difference in patients' lives."
February 9, 2009
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information visit http://www.astrazeneca-us.com./
About Mayo Clinic's Office of Intellectual Property
Mayo Clinic has one of the most highly evolved intellectual property and technology commercialization efforts in academic medicine, with a 20-year history of supporting Mayo's mission. The Office of Intellectual Property at Mayo Clinic, serves as a bridge between discoveries and the marketplace. Our staff works closely with Mayo physicians and scientists to evaluate and develop inventions, ideas and discoveries that have the potential to transform healthcare and generate income to support Mayo patient care, education and research. At Mayo Clinic, we work with inventors and industry to determine the right fit for each innovation, whether a sponsored research agreement, licensing agreement, technology-based venture, start-up company or entirely new business model. Mayo Clinic's Office of Intellectual Property has filed more than 2,800 patent applications resulting in more than 500 active licensing agreements with companies in the biomedical and manufacturing industries.
For more information, visit www.mayoclinic.org
Det betyder nu endnu et big pharma selsskab anser TRI som den næste generations anti lykkepiller.
NS2359 er det TRI stof der er længst fremme i udviklingen. Resultater fra de 2 fase 2b forsøg bør foreligge seneste medio marts. (resultatet fra det ene forsøg har været kendt af GSK og muligvis også NS i mere end 1 mdr)
AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
Posted February 9, 2009
AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
Agreement includes research collaboration to generate follow-up TRI compounds
WILMINGTON, Del., Feb. 9 /PRNewswire-FirstCall/ -- AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds. The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds. Financial details were not disclosed.
Current classes of antidepressant therapies such as selective serotonin (SSRI) and dual serotonin/norepinephrine (SNRI) reuptake inhibitors are proven treatments for depression and anxiety. However, they only address the imbalances of one or two of the neurotransmitters in the brain.
Paul R. Carlier, Professor of Organic and Medicinal Chemistry at Virginia Tech, explains, "Together with our colleagues at Mayo Clinic, we have been seeking wider-spectrum behavior and have developed a portfolio of TRIs to address imbalances associated with the three major neurotransmitters. Besides incorporating all the benefits associated with serotonin and norepinephrine inhibition, our TRI compounds include the additional action of the dopamine neurotransmitter. We are excited to discover additional compounds that work through this unique mechanism."
Elliott Richelson, M.D., Mayo Clinic, co-inventor of the technology adds, "Through our clinical practice, we recognize the need for improved therapies to treat individuals suffering from depression or anxiety. The additional dopamine action of our TRI compounds has the potential to deliver a superior antidepressant in terms of greater efficacy and an improved side effect profile. By collaborating with AstraZeneca, a company with a strong history of developing new medicines, we have the opportunity to both advance and expand upon these scientific discoveries to address better the needs of patients worldwide."
Christer Kohler, Vice President for AstraZeneca's Global Discovery Research Area focused on Central Nervous System & Pain, says "Besides enabling us to harness the combined power of two outstanding, world-class institutions, this agreement also establishes a strong footing for AstraZeneca in the strategically important TRI research area. We continue to build alliances and collaborations within the scientific community and this deal is another example of our strong commitment and ability to leverage innovation with the aim of making a meaningful difference in patients' lives."
February 9, 2009
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information visit http://www.astrazeneca-us.com./
About Mayo Clinic's Office of Intellectual Property
Mayo Clinic has one of the most highly evolved intellectual property and technology commercialization efforts in academic medicine, with a 20-year history of supporting Mayo's mission. The Office of Intellectual Property at Mayo Clinic, serves as a bridge between discoveries and the marketplace. Our staff works closely with Mayo physicians and scientists to evaluate and develop inventions, ideas and discoveries that have the potential to transform healthcare and generate income to support Mayo patient care, education and research. At Mayo Clinic, we work with inventors and industry to determine the right fit for each innovation, whether a sponsored research agreement, licensing agreement, technology-based venture, start-up company or entirely new business model. Mayo Clinic's Office of Intellectual Property has filed more than 2,800 patent applications resulting in more than 500 active licensing agreements with companies in the biomedical and manufacturing industries.
For more information, visit www.mayoclinic.org
10/2 2009 00:43 troldmanden 0
2368 February 9, 2009, 2:32 pm
For Antidepressants, Maybe Three Targets Will Be Better than Two
Posted by Jeanne Whalen
AstraZeneca said today that it’s partnering with the Mayo Clinic and Virginia Tech to work on an experimental class of antidepressants known as triple reuptake inhibitors, or TRIs.
The drugs target three brain chemicals believed to be involved in depression — serotonin, norepinephrine and dopamine. Existing drugs target just serotonin, or serotonin and norepinephrine.
The project announced today has yet to test a TRI in people. That puts AstraZeneca a bit behind some other drug makers. In 2007, Danish firm NeuroSearch said it was carrying out a phase-2 study on a TRI with GlaxoSmithKline. Bristol-Myers Squibb has worked with Albany Molecular Research Inc. on similar drugs, and Dov Pharmaceutical said last year it was starting a phase-2 study on a TRI.
By adding dopamine to the mix, drug makers hope to crack certain types of depression that typically don’t respond to drug treatment, including melancholic depression, Christer Köhler, vice president of global discovery research at AstraZeneca, told the Health Blog.
“We know that dopamine is involved and plays an important role in motivation and reward,” he said. “There is a whole spectrum of how you segment various depressed states. More atypical depressions could respond well [to TRIs], because the belief is that dopamine could be more involved” in these depressions, he said.
Still, it’s way too early to get too excited about these drugs. Lots of drugs seem promising in early development, only to wash out for unpredictable reasons in late stage testing.
The partners did not disclose financial terms of the deal. In a statement, AstraZeneca said it is licensing a portfolio of preclinical drugs from the institutions, and establishing a research collaboration with them to look for other compounds.
For Antidepressants, Maybe Three Targets Will Be Better than Two
Posted by Jeanne Whalen
AstraZeneca said today that it’s partnering with the Mayo Clinic and Virginia Tech to work on an experimental class of antidepressants known as triple reuptake inhibitors, or TRIs.
The drugs target three brain chemicals believed to be involved in depression — serotonin, norepinephrine and dopamine. Existing drugs target just serotonin, or serotonin and norepinephrine.
The project announced today has yet to test a TRI in people. That puts AstraZeneca a bit behind some other drug makers. In 2007, Danish firm NeuroSearch said it was carrying out a phase-2 study on a TRI with GlaxoSmithKline. Bristol-Myers Squibb has worked with Albany Molecular Research Inc. on similar drugs, and Dov Pharmaceutical said last year it was starting a phase-2 study on a TRI.
By adding dopamine to the mix, drug makers hope to crack certain types of depression that typically don’t respond to drug treatment, including melancholic depression, Christer Köhler, vice president of global discovery research at AstraZeneca, told the Health Blog.
“We know that dopamine is involved and plays an important role in motivation and reward,” he said. “There is a whole spectrum of how you segment various depressed states. More atypical depressions could respond well [to TRIs], because the belief is that dopamine could be more involved” in these depressions, he said.
Still, it’s way too early to get too excited about these drugs. Lots of drugs seem promising in early development, only to wash out for unpredictable reasons in late stage testing.
The partners did not disclose financial terms of the deal. In a statement, AstraZeneca said it is licensing a portfolio of preclinical drugs from the institutions, and establishing a research collaboration with them to look for other compounds.
